INPP5D
6
MENTIONS
2
EPISODES
1
PODCASTS
Search complete. 6 mentions across 2 episodes found for "INPP5D".
Sep 10, 2026
Islam MohamedGUEST
So in laboratory and animal studies, it demonstrates two distinct behaviors.
Islam MohamedGUEST
In tumors that have lost a tumor suppressor gene, one called PTEN or P10, and another one called SHIP1, It can kill cancer cells acting via synthetic lethality just with the drug alone.
Islam MohamedGUEST
And where those genes are intact, it can also act as a sensitizer.
Islam MohamedGUEST
So it can prevent the tumor from repairing damage that radiation treatment or DNA damaging chemotherapy can inflict.
12 MINS LATER
Islam MohamedGUEST
The first is through biomarker-selected monotherapy in P10 or SHP1-deficient tumors.
Islam MohamedGUEST
P10 deficiency, it occurs frequently in advanced solid tumors like glioblastoma or common cancers like prostate cancer, colorectal cancer, endometrial and ovarian cancer, breast cancer.
Islam MohamedGUEST
So P10 deficiency occurs frequently in relatively common tumors, and hematologic malignancies are where SHIP1 deficiency is likely.
Islam MohamedGUEST
So it occurs in Hodgkin lymphoma and the more common non-Hodgkin lymphomas.
Islam MohamedGUEST
So, you know, for us, we anticipate that our two modes of action yield two markets.
Islam MohamedGUEST
The first is through biomarker-selected monotherapy in P10 or SHIP1 deficient tumors.
Islam MohamedGUEST
So P10 deficiency, it occurs frequently in advanced solid tumors like glioblastoma or common cancers like prostate cancer, colorectal cancer, endometrial and ovarian cancer, breast cancer.
Islam MohamedGUEST
So P10 deficiency occurs frequently in relatively common tumors, and hematologic malignancies are where SHIP1 deficiency is likely.
Islam MohamedGUEST
So it occurs in Hodgkin lymphoma and the more common non-Hodgkin lymphomas.
Islam MohamedGUEST
So your listeners might have heard of diffuse large B-cell lymphoma or follicular lymphoma or peripheral T-cell lymphoma.
Islam MohamedGUEST
SHIP1 deficiency is very common in these lymphomas.
Islam MohamedGUEST
So that's one mode of action, that biomarker-selected therapy, and one market.